Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02646475 · ClinicalTrials.gov registry record · Phase 1
Metabolic Effects of Angiotensin-(1-7)
A Phase 1 study of Obesity and Hypertension, sponsored by Vanderbilt University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02646475: Recruiting Phase 1 study of Obesity and Hypertension, sponsored by Vanderbilt University.
NCT02646475 is a Phase 1 study of Obesity and Hypertension that is actively recruiting participants, run by Vanderbilt University. The registered enrollment target is 26 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02646475, a Phase 1 study of Obesity and Hypertension, is actively recruiting participants, sponsored by Vanderbilt University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Primary Outcome
Whole-body insulin sensitivity will be defined as the glucose infusion rate needed to maintain euglycemia during steady state (time=90 to 120 minutes) of the hyperinsulinemic-euglycemic clamp following angiotensin-(1-7) versus saline infusion. The insulin sensitivity will be corrected by body weight, lean body mass, and steady-state plasma insulin concentrations.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Angiotensin-(1-7)
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-02 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
What NCT02646475 shows while recruiting
NCT02646475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT02646475 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02646475 about?
NCT02646475 is a clinical study titled "Metabolic Effects of Angiotensin-(1-7)". The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related dis...
What is the current status of trial NCT02646475?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2016-02. Estimated completion is 2029-12.
What conditions does trial NCT02646475 study?
This clinical trial studies the following conditions: Obesity, Hypertension, Insulin Resistance, Metabolic Cardiovascular Syndrome.
What interventions are being tested in trial NCT02646475?
The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT02646475?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02646475 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02646475's enrollment target sits among peer trials
26 897th of 1053 higher than 151 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
- NCT04913064 · 26 participants · NA
Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia